The anti-liver fibrosis effect of Kangxian Ruangan prescription: A cell study based on hepatic sinusoidal capillarization

Xu Jie; Liu Yan; Lou WangZhouYang; Xu Jun; Qi Lu; Cheng LiangBin

doi:10.3969/j.issn.1001-5256.2020.02.017

Volume 36 Issue 2

Feb. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(2): 319-323

PDF( 2259 KB)

The anti-liver fibrosis effect of Kangxian Ruangan prescription: A cell study based on hepatic sinusoidal capillarization

DOI: 10.3969/j.issn.1001-5256.2020.02.017

Clinical College of Traditional Chinese Medicine,Hubei University of Chinese Medicine

Research funding:

Received Date: 2019-09-15
Published Date: 2020-02-20

Abstract

Abstract

Objective To investigate the anti-liver fibrosis effect and mechanism of action of Kangxian Ruangan prescription based on hepatic sinusoidal capillarization. Methods A total of 16 male Wistar rats were divided into Kangxian Ruangan prescription group and control group,with 8 rats in each group. The rats in the Kangxian Ruangan prescription group were given crude drug 40 g/kg body weight by gavage,and those in the control group were given normal saline by gavage. Serum containing Kangxian Ruangan prescription was prepared,and then primary liver sinusoidal endothelial cells were treated with the serum containing Kangxian Ruangan prescription or the control serum. Western blot was used to measure the protein expression of the vascular endothelial markers cluster of differentiation 31( CD31) and von Willebrand factor( vWF),and immunocytochemistry was used to measure the expression of CD31 and vWF in cells. Scanning electron microscopy was used to observe the change in the fenestrae of liver sinusoidal endothelial cells. The t-test was used for comparison of continuous data between two groups. Results Kangxian Ruangan prescription had no marked influence on the morphology of liver sinusoidal endothelial cells. The liver sinusoidal endothelial cells in the control group had a small number of narrow fenestrae with an occluded structure,while those in the Kangxian Ruangan prescription group had an increased number of large fenestrae with a clear structure. The results of immunocytochemistry showed that compared with the control group,the Kangxian Ruangan prescription group had significant reductions in the expression of CD31( 0. 069 ± 0. 015 vs 0. 115 ± 0. 011,t = 4. 257,P < 0. 05) and vWF( 0. 092 ± 0. 009 vs 0. 132 ± 0. 014,t = 4. 274,P < 0. 05). The results of Western blot showed that compared with the control group,the Kangxian Ruangan prescription group had significant reductions in the protein expression of CD31( 0. 334 ± 0. 029 vs 0. 448 ± 0. 013,t = 6. 245,P < 0. 01) and vWF( 0. 560 ± 0. 047 vs0. 709 ± 0. 045,t = 3. 966,P < 0. 05). Conclusion Kangxian Ruangan prescription can significantly resist hepatic sinusoid capillarization and thus prevent the progression of liver fibrosis.
- liver cirrhosis,
- Kangxian ruangan decoction,
- antigens,CD31,
- von Willebrand factor,
- rats,Wistar

FullText(HTML)

References(27)

References

[1] ZHOU XG,LIU HG. Hedgehog signaling pathway in liver diseases[J/CD]. Chin J Liver Dis(Electronic Version),2017,9(3):30-35.(in Chinese)周新刚，刘红刚．Hedgehog信号通路在肝脏疾病中的研究进展[J/CD]．中国肝脏病杂志(电子版)，2017,9(3):30-35.

[2] IREDALE JP. Models of liver fibrosis:Exploring the dynamic nature of inflammation and repair in a solid organ[J]. J Clin Invest,2007,117(3):539-548.

[3] SCHUPPAN D,KIM YO. Evolving therapies for liver fibrosis[J]. J Clin Invest,2013,123(5):1887-1901.

[4] GU L,TAO X,XU Y,et al. Dioscin alleviates BDL-and DMN-induced hepatic fibrosis via Sirt1/Nrf2-mediated inhibition of p38 MAPK pathway[J]. Toxicol Appl Pharmacol,2016,292:19-29.

[5] SUN NN,SUN FX,LI XL,et al. Significance of the treatment of basic liver diseases in primary liver cancer[J/CD]. Chin J Liver Dis(Electronic Version),2018,10(1):6-9.(in Chinese)孙宁宁，孙凤霞，李晓玲，等．原发性肝癌基础肝病治疗的意义[J/CD]．中国肝脏病杂志(电子版)，2018,10(1):6-9.

[6] LYU GS,CHEN L,WANG HY. Research progress and prospect of liver cancer in China[J]. Chin Bull Life Sci,2015,27(3):237-248.(in Chinese)吕桂帅，陈磊，王红阳．我国肝癌研究的现状与前景[J]．生命科学，2015,27(3):237-248.

[7] ZHANG H,TAO S,HAO Y,et al. Research highlights analysis of foreign liver fibrosis diagnosis[J]. J Capital Medical University,2016,37(1):83-88.(in Chinese)张弘，陶森，郝彧，等．国外肝纤维化诊断的研究热点分析[J]．首都医科大学学报，2016,37(1):83-88.

[8] XIE ZB,YU YQ,FENG DY,et al. Fuzheng Huayu recipe promotes the fenestration of capillarization in Iiver sinusoidal endothelial cells[J]. J Cent South Univ:Med Sci,2015,40(7):723-728.(in Chinese)谢知兵，余燕青，冯德云，等．扶正化瘀方增加毛细血管化肝窦内皮细胞窗孔结构[J]．中南大学学报:医学版，2015,40(7):723-728.

[9] JIA YT,ZENG MD. Research progress of hepatic sinusoidal capillarization[J]. Foreign Med Sci:Digive System Dis,2000,20(2):86-90.(in Chinese)贾一韬，曾明德．肝窦毛细血管化的研究进展[J]．国外医学:消化系疾病分册，2000,20(2):86-90.

[10] XU MX,XU RY,LIN N,et al. Research progress of hepatic sinusoidal capillarization[J]. Organ Transplantation,2016,7(5):403-406.(in Chinese)许明星，许瑞云，林楠，等．肝窦毛细血管化研究进展[J]．器官移植，2016,7(5):403-406.

[11] ZHANG CZ,WANG L. 31 cases of liver cirrhosis treated by anti-fibrosis and soft liver impulse[J]. Chin J Integr Tradit West Med Liver Dis,1999,9(2):19-20.(in Chinese)张赤志，王丽．抗纤软肝冲击治疗肝硬变31例[J]．中西医结合肝病杂志，1999,9(2):19-20.

[12] CHENG LB,CHENG M,LIU Y,et al. The effect of Kangxian Ruangan granule on the expression of nuclear factor-κB in fibrotic rat liver[J]. J Clin Hepatol,2010,26(4):410-412.(in Chinese)程良斌，程铭，刘艳，等．抗纤软肝颗粒对肝纤维化大鼠肝组织核因子-κB基因表达的影响[J]．临床肝胆病杂志，2010,26(4):410-412.

[13] CAI YP,CHENG LB,LI ZW,et al. Effects of Kangxian Ruangan granule on hepatic stellate cell cycle of rat[J]. Chin J Integr Tradit West Med Liver Dis,2013,23(4):234-236.(in Chinese)蔡艳萍，程良斌，李志伟，等．抗纤软肝颗粒对大鼠肝星状细胞周期的影响[J]．中西医结合肝病杂志，2013,23(4):234-236.

[14] HUANG LW,CHENG LB. Advances in anti-hepatic fibrosis of traditional Chinese medicine targeting hepatic stellate cells[J]. Chin J Integr Tradit West Med Liver Dis,2007,17(3):191-193.(in Chinese)黄丽雯，程良斌．中药以肝星状细胞为靶点的抗肝纤维化研究进展[J]．中西医结合肝病杂志，2007,17(3):191-193.

[15] CHENG LB,LI ZW. Effect of Kangxian Ruangan granule on HSC nucleolar non-histone protein B23 and C23 of rats[J]. Chin J Integr Tradit West Med Liver Dis,2010,20(5):291-293.(in Chinese)程良斌，李志伟．抗纤软肝颗粒对大鼠肝星状细胞核仁非组蛋白B23和C23的影响[J]．中西医结合肝病杂志，2010,20(5):291-293.

[16] YAN JS,ZHOU JH,CHENG LB. Effect of Kangxian Ruangan granules on hepatic fibrosis induced by carbon tetrachloride and ethanol[J]. Chin J Integr Tradit West Med Liver Dis,2017,27(1):40-41,49.(in Chinese)严俊松，周金辉，程良斌．抗纤软肝颗粒对四氯化碳加乙醇诱导肝纤维化大鼠的影响[J]．中西医结合肝病杂志，2017,27(1):40-41,49.

[17] JIANG MH,LIU L,MENG YP,et al. Clinical study of Kangxian Ruangan granule in the treatment of liver fibrosis[J]. Guid J Tradit Chin Med Pharm,2016,22(14):81-83.(in Chinese)蒋满红，刘璐，孟艳平，等．抗纤软肝颗粒治疗肝纤维化的临床研究[J]．中医药导报，2016,22(14):81-83.

[18] LI ZW,CHENG LB. Effects of Kangxian Ruangan granule on rat hepatic stellate cell proliferation[J]. Chin J Integr Tradit West Med Liver Dis,2010,20(2):95-97.(in Chinese)李志伟，程良斌．抗纤软肝颗粒对大鼠肝星状细胞增殖的影响[J]．中西医结合肝病杂志，2010,20(2):95-97.

[19] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol,2019,35(10):2163-2172.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．肝纤维化诊断及治疗共识(2019年)[J]．临床肝胆病杂志，2019,35(10):2163-2172.

[20] LOK AS. Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2013,10(4):199-200.

[21] MARCELLIN P,GANE E,BUTI M,et al. Regression of cirrhosisduring treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open label follow up study[J]. Lancet,2013,381(9865):468-475.

[22] CHANG TT,LIAW YF,WU SS,et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology,2010,52(3):886-893.

[23] JIN WZ,TAN XC,WEN J,et al. Advances in nano-delivery systems targeting hepatic stellate cells for hepatic fibrosis[J].China Med Herald,2019,16(9):34-37.(in Chinese)靳雯臻，谭晓川，文瑾，等．靶向肝星状细胞治疗肝纤维化的纳米递送系统研究进展[J]．中国医药导报，2019,16(9):34-37.

[24] JIA JD,YIN SS. Diagnosis and treatment of liver fibrosis[J].J Clin Intern Med,2002,19(4):244-247.(in Chinese)贾继东，尹珊珊．肝纤维化的诊断和治疗进展[J]．临床内科杂志，2002,19(4):244-247.

[25] DENG C,YE BP. Research progress in mechanism and treatment of hepatic fibrosis[J]. Pharm Bio Technol,2017,24(5):454-458.(in Chinese)邓灿，叶波平．肝纤维化发生机制及治疗研究进展[J]．药物生物技术，2017,24(5):454-458.

[26] YU ZY,LIN X,HAN Y,et al. Role of liver sinusoidal endothelial cells in liver regeneration and the development of liver fibrosis[J]. J Clin Hepatol,2019,35(9):2072-2074．于子越，蔺鑫，韩英，等．肝血窦内皮细胞在肝再生和肝纤维化发生中的作用[J]．临床肝胆病杂志，2019,35(9):2072-2074.

[27] LU X,LIU P,LIU CH,et al. Experimental study on the effect of Fuzheng Huayu Recipe on reversing hepatic sinusoidal capillarization in rats with dimethylnitrosamine-induced hepatic fibrosis[J]. J Tradit Chin Med,2003,44(2):136-139.(in Chinese)陆雄，刘平，刘成海，等．扶正化瘀方促进二甲基亚硝胺肝纤维化大鼠肝窦毛细血管化逆转作用的实验研究[J]．中医杂志，2003,44(2):136-139.

Relative Articles

[1]	Hui HUANG, Lieming XU, Jian PING, Yang ZHOU. Value of Fuzheng Huayu prescription in preventing liver fibrosis by altering the phenotypic function of CD8⁺ T lymphocytes in the liver of mice with acute liver injury[J]. Journal of Clinical Hepatology, 2022, 38(2): 342-346. doi: 10.3969/j.issn.1001-5256.2022.02.017
[2]	Caijun HAN, Yuan HUANG, Bin NIAN, Meihua PIAO. Value of von Willebrand factor antigen-to-albumin ratio and glycocalicin index in predicting esophageal varices in hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2750-2754. doi: 10.3969/j.issn.1001-5256.2022.12.013
[3]	Xue Miao, Mao XiaoRong, Chen Hong. Change in T helper 17 cell/regulatory T cell imbalance in rats with immunological liver injury[J]. Journal of Clinical Hepatology, 2020, 36(1): 149-152. doi: 10.3969/j.issn.1001-5256.2020.01.033
[4]	Jiang Yu, Hu JuLong, Ma JiaLi, Li Ping, Zhou YuLing, Liang XiuXia, Ai ZhengLin, Yao ShuKun. Antioxidant effect of berberine in a rat model of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1273-1276. doi: 10.3969/j.issn.1001-5256.2018.06.028
[5]	Lu Lu, Wu Chao, Xie Dong, An YongTong, Zhao YaHong, Ye Guan, Sun MingYu. Preventive and therapeutic effects of Babaodan on hepatic encephalopathy in rats with acute liver failure[J]. Journal of Clinical Hepatology, 2018, 34(12): 2635-2641. doi: 10.3969/j.issn.1001-5256.2018.12.025
[6]	Niu XueMin, Wang BaoYu, Wang Yang, Zhao Wen, Fu Na, Zhao SuXian, Du JingHua, Wang RongQi, Zhang YuGuo, Nan YueMin. Role of phosphatase and tensin homolog deleted on chromosome ten in a rat model of carbon tetrachloride-induced liver fibrosis and the effect of qi-tonifying and blood-activating prescription[J]. Journal of Clinical Hepatology, 2018, 34(1): 122-128. doi: 10.3969/j.issn.1001-5256.2018.01.025
[7]	Xu Feng, Liu XiaoLin, Wang Chao, Dai ChaoLiu. Protective effect of prostaglandin E1 pretreatment against liver ischemia-reperfusion injury in rats with cholestasis[J]. Journal of Clinical Hepatology, 2017, 33(5): 899-904. doi: 10.3969/j.issn.1001-5256.2017.05.022
[8]	An BaiQuan, Xin YongNing, Lu LinLin, Xuan ShiYing. Effect of PNPLA3 I148M mutation on expression of TGF- β1 in rat hepatic stellate cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 769-771. doi: 10.3969/j.issn.1001-5256.2016.04.035
[9]	Cai Qi, Yan WeiWei, Wang ShaoKun, Wu Yang. Protective effect of Cordyceps militaris polypeptide against acute alcoholic liver injury in rats[J]. Journal of Clinical Hepatology, 2016, 32(4): 669-672. doi: 10.3969/j.issn.1001-5256.2016.04.011
[10]	Chen Bin, Xu JiaYu, Peng Jie, He Wan, Li Wu, Su XuChu, Sun KeWei. Effect of “treating liver by nourishing spleen”on gut microbiota in rats with liver fibrosis based on Xiaoyao powder and its separated recipe[J]. Journal of Clinical Hepatology, 2016, 32(4): 657-662. doi: 10.3969/j.issn.1001-5256.2016.04.009
[11]	Xu ShanShan, Chen YaLi, Zhang Jing. Role of ADAMTS13 in diagnosis and pathogenesis of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 390-392. doi: 10.3969/j.issn.1001-5256.2016.02.043
[12]	Wen Nuan, Zhu YiXiang, Lu: RenGeng, Kang JiangHui, Han HongJun, Xu HanBin. Expression and significance of UCP-2 in rats with obstructive jaundice and bile flow restoration[J]. Journal of Clinical Hepatology, 2015, 31(1): 88-92. doi: 10.3969/j.issn.1001-5256.2015.01.019
[13]	Liu XiaoYa, Liu RuiXia, Cui LiJian, Hou Fei, Wen Yan, Yin ChengHong. Comparison of hepatic fibrosis models and associated hepatic fibronectin expression in Wistar rats treated by bile duct ligation and CCl4[J]. Journal of Clinical Hepatology, 2015, 31(2): 219-224. doi: 10.3969/j.issn.1001-5256.2015.02.018
[14]	Lu LunGen, Li ZhengHong. Recent research on liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(5): 321-323.
[15]	Wei SiChen, Zheng GuoQi. Role of adipokine in the pathogenesis of cirrhosis of the liver[J]. Journal of Clinical Hepatology, 2012, 28(1): 78-81.
[16]	Shao XiaoDong, Guo XiaoZhong, Wang Di, Zou DeLi, Ren LiNan, Li HongYu, Zhao JiaJun. The effects of CD34+ cell on the efficacy of autologous bone marrow stem cell transplantation in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 127-129.
[17]	Cheng LiangBin, Cheng Ming, Liu Yan. The effect of Kangxian ruangan granule on the expression of nuclear factor-κB gene in fibrotic rat liver[J]. Journal of Clinical Hepatology, 2010, 26(4): 410-412.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	彭岳，杨妙，林江，赵铁建，刘鹏，刘茜玉，郭伟倩. 莪术醇干预肝纤维化病程中的肝窦毛细血管化病变的研究. 辽宁中医杂志. 2024(12): 9-14+237 .
2.	唐舒高，刘文兰. 中医药治疗肝纤维化的研究进展. 中国现代医生. 2023(18): 123-126 .
3.	王佳慧，郑洋，汪磊，黄艳青，段雪琳，刘艳芳，赵铁建，梁天坚. miR-125b对肝脏血管新生调控作用的实验研究. 安徽医科大学学报. 2023(12): 2051-2057 .
4.	韩才均，黄媛，粘彬，朴美花. 血管性血友病因子抗原与白蛋白比值和糖萼素指数评分对乙型肝炎肝硬化食管静脉曲张的预测价值. 临床肝胆病杂志. 2022(12): 2750-2754 . 本站查看
5.	徐俊，戚璐，冉思燕，周涛，许杰，程良斌，张赤志. 抗纤软肝颗粒通过调节肠道菌群防治肝纤维化. 时珍国医国药. 2022(10): 2389-2393 .
6.	张冰冰，梁健，邓鑫，张艳培，徐粤娟. 中医药抗肝纤维化作用机制研究进展. 湖南中医杂志. 2021(08): 191-193 .
7.	徐俊，戚璐，郑新平，周涛，李硕，胡聪，程良斌. 抗纤软肝颗粒对肝纤维化小鼠PI3K/Akt/mTOR信号通路的作用. 中医药导报. 2020(14): 4-8 .
8.	徐俊，戚璐，许杰，向阳，周涛，李硕，程良斌. 基于TLR4/MyD88/NF-κB信号通路探讨抗纤软肝方抗肝纤维化的实验研究. 时珍国医国药. 2020(12): 2908-2911 .

Other cited types(8)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1427) PDF downloads(226)

The anti-liver fibrosis effect of Kangxian Ruangan prescription: A cell study based on hepatic sinusoidal capillarization

DOI: 10.3969/j.issn.1001-5256.2020.02.017